BGB-3111-206 Trial

BGB-3111-206 (NCT03206970) is a Phase 2, multicenter, single-arm, open-label trial of zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).

BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.

BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.